Recombinant Human VEGF 165 (E. coli-expressed) Protein, CF

As an alternative, please consider our next generation Recombinant Human VEGF 165 (BT-VEGF). It has equivalent bioactivity to Recombinant Human VEGF 165 (Catalog # 10318-VE). It combines R&D Systems quality with scalability that allows for a solid supply chain. Both Recombinant Human VEGF 165 proteins are measured in a cell proliferation assay using HUVEC human umbilical vein endothelialcells.

Product Discontinued

Recombinant Human VEGF 165 (E. coli-expressed) Protein, CF Summary

• Details of Functionality: Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323. The ED₅₀ for this effect is 1.50-12.0 ng/mL.
• Source: E. coli-derived human VEGF protein
  Ala27-Arg191
• Accession #: NP_001165097
• N-terminal Sequence: Met & Pro28
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 19 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 19-22 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in HCl.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS. Alternatively, reconstitute at 100-500 μg/mL in sterile 4 mM HCl..

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VEGF 165 (E. coli-expressed) Protein, CF

• MVCD1
• VAS
• vascular endothelial growth factor A
• Vascular permeability factor
• Vasculotropin
• VEGF
• VEGFA
• VEGF-A
• VEGFMGC70609
• VPF
• VPFvascular endothelial growth factor

Background

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1-3). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure (4). Humans express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length (4). VEGF₁₆₅ appears to be the most abundant and potent isoform, followed by VEGF₁₂₁ and VEGF₁₈₉ (3, 4). Isoforms other than VEGF₁₂₁ contain basic heparin-binding regions and are not freely diffusible (4). Human VEGF₁₆₅ shares 88% aa sequence identity with corresponding regions of mouse and rat, 96% with porcine, 95% with canine, and 93% with feline, equine and bovine VEGF, respectively. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells (4). Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). VEGF₁₆₅ binds the semaphorin receptor, Neuropilin-1 and promotes complex formation with VEGF R2 (5). VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells (3, 4). In adults, VEGF functions mainly in wound healing and the female reproductive cycle (3). Pathologically, it is involved in tumor angiogenesis and vascular leakage (6, 7). Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (8). VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, oncostatin M and TNF-alpha (3, 4, 9).

Due to its role in angiogenesis of blood vessels, tumor and stroma cells use VEGF to stimulate formation of blood vessels and the proliferation and survival of endothelial cells. Specific immunotherapies targeting the VEGF signaling pathway include the recombinant antibody against VEGF (Bevacizumab), antibodies targeting the main VEGF receptor (VEGFR2), and small molecule inhibitors against VEGF receptor tyrosine kinases (10). Immune checkpoint inhibitors are an important tool in cancer therapies as tumor cells can hijack immune checkpoint signals to evade detection by immune cells. In addition to stimulating the formation of tumor blood vessels, VEGF has immunosuppressive effects by acting on dendritic cells to block their antigen-presenting and T cell stimulatory functions. Targeting VEGF in combination with other immune checkpoint ligands or receptors may prove more effective in immunotherapy approaches to certain cancer types (11). Because of its role in the formation of blood vessels, VEGF is also an important factor in skeletal development where blood supply and vascularization are crucial. This has made VEGF an important molecule in regenerative studies for bone repair as sustained release of VEGF has been shown to improve the efficiency of bone regeneration (12).

In differentiation protocols for stems cells, VEGF is a commonly added growth factor for the transformation of induced pluripotent stem cells into hematopoietic progenitor cells used to make Natural Killer cells (13, 14). VEGF has also been used to transform intermediate mesoderm into kidney glomerular podocytes or stem cell-derived liver spheres (15, 16). VEGF may also be used in assistance of stem cell transplantations by supporting angiogenesis at sites of stem cell transplants or as a honing tool for adipose-derived mesenchymal stem cells or bone marrow stem cells to migrate to (17, 18).

1. Leung, D.W. et al. (1989) Science 246:1306.
2. Keck, P.J. et al. (1989) Science 246:1309.
3. Byrne, A.M. et al. (2005) J. Cell. Mol. Med. 9:777.
4. Robinson, C.J. and S.E. Stringer (2001) J. Cell. Sci. 114:853.
5. Pan, Q. et al. (2007) J. Biol. Chem. 282:24049.
6. Weis, S.M. and D.A. Cheresh (2005) Nature 437:497.
7. Thurston, G. (2002) J. Anat. 200:575.
8. Carvalho, J.F. et al. (2007) J. Clin. Immunol. 27:246.
9. Angelo, L.S. and R. Kurzrock (2007) Clin. Cancer Res. 13:2825.
10. Apte, R.S. et al. (2019) Cell 176(6):1248.
11. Sangro, B. et al. (2021) Nature 18:525-543.
12. Hu, K. & Olsen, B.R. (2016) Bone 91:30-38.
13. Zhou, Y. et al. (2022) Cancers 14:2266.
14. Li, Y. et al. (2018) Cell Stem Cell 23(2):181-192.
15. Musah, S. et al. (2018) Nat. Protoc. 13(7):1662-1685.
16. Meseguer-Ripolles, J. et al. (2021) STAR Protoc. 2(2):100502.
17. Hutchings, G. et al. (2020) Int. J. Mol. Sci. 21(11):3790.
18. Zhang, W. et al. (2014) Euro Cell and Mater. 27:1-12.

FAQs for VEGF (10318-VE). (Showing 1 - 1 of 1 FAQ).

1. Why is the molecular weight of VEGF different from the similar antibody, for some companies the the molecular weight is 40KD)?
   • I can't comment on another company's antibody because I don't have any information about their products. I can tell you that VEGF is expressed in a variety of isoforms and is subject to various post-translational modifications that influence its apparent molecular weight in an SDS-PAGE gel compared to the theoretical molecular weight.

Bioinformatics

• Uniprot:
  • NP_001165097()